More recently, we have demonstrated epigenetic silencing of EMX2 expression in lung adenocarcinomas and its association with poor clinical outcomes in early stage lung adenocarcinoma patients [17, 18]. The gene discussed is EMX2; the disease is lung adenocarcinoma.